Table 1 |
||
|
Demographic and clinical features of the patients studied |
||
| APS |
SLE |
|
|
|
||
| (n = 18) |
(n = 10) |
|
| Females/Males |
15/3 |
9/1 |
| Age in years |
||
| Mean (range) |
38.4 (28–68) |
36.9 (18–59) |
| Disease duration in months |
||
| Mean (range) |
121 (1–322) |
119 (12–300) |
| Vascular thrombosis |
||
| Venous thrombosis (percentage) |
14/18 (77.7) |
0 |
| Arterial thrombosis (percentage) |
8/18 (44.4) |
0 |
| Recurrent thrombosis (percentage) |
4/14 (28.5) |
0 |
| Pregnancy morbidity |
||
| Normal foetus deaths (percentage) |
0 |
0 |
| Premature births (percentage) |
1/18 (5.5) |
0 |
| Spontaneous abortions (percentage) |
9/18 (50) |
0 |
| Serological features |
||
| aCL IgG (percentage) |
18/18 (100) |
10/10 (100) |
| aCL IgM (percentage) |
11/18 (61) |
5/10 (50) |
| Anti-β2-GPI IgG |
18/18 (100) |
10/10 (100) |
| Anti-β2-GPI IgM |
ND |
ND |
| Lupus anticoagulant activity (percentage)a |
15/18 (83.3) |
5/10 (50) |
|
|
||
|
aLupus anticoagulant activity was deduced from recent clinical records. aCL, anticardiolipin antibody; APS, antiphospholipid syndrome; β2-GPI, beta2-glycoprotein I; IgG, immunoglobulin G; IgM, immunoglobulin M; ND, not done; SLE, systemic lupus erythematosus. |
||
|
Alessandri et al. Arthritis Research & Therapy 2006 8:R180 doi:10.1186/ar2091 |
||
